Novartis AG ADR (NVS): Price and Financial Metrics

NVS POWR Grades

• Growth is the dimension where NVS ranks best; there it ranks ahead of 97.28% of US stocks.
• NVS's strongest trending metric is Growth; it's been moving up over the last 157 days.
• NVS ranks lowest in Momentum; there it ranks in the 16th percentile.

NVS Stock Summary

• NVS has a market capitalization of $209,762,910,000 -- more than approximately 99.31% of US stocks.
• In terms of twelve month growth in earnings before interest and taxes, NOVARTIS AG is reporting a growth rate of -65.83%; that's higher than merely 20.95% of US stocks.
• NOVARTIS AG's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 9.58%, greater than the shareholder yield of 81.54% of stocks in our set.
• If you're looking for stocks that are quantitatively similar to NOVARTIS AG, a group of peers worth examining would be PFE, CSCO, ABBV, NFLX, and SAP.
• Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to www.novartis.com.

NVS Valuation Summary

• In comparison to the median Healthcare stock, NVS's price/sales ratio is 21.57% lower, now standing at 4.
• NVS's EV/EBIT ratio has moved up 8.4 over the prior 243 months.

Below are key valuation metrics over time for NVS.

NVS Growth Metrics

Its 2 year revenue growth rate is now at 6.14%.
• Its year over year net income to common stockholders growth rate is now at 204.01%.
• Its 2 year net cashflow from operations growth rate is now at 6.18%.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

NVS's Quality Factors

• NVS has a Quality Grade of B, ranking ahead of 86.01% of graded US stocks.
• NVS's asset turnover comes in at 0.42 -- ranking 108th of 682 Pharmaceutical Products stocks.
• GHSI, KALA, and ADAP are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.